UK medicines proposal threatens medical device manufacturers with easier prosecution
This article was originally published in Clinica
UK Medical device and diagnostic manufacturers could face prosecution if they wrongly classify products the UK Medicines Control Agency (MCA) deems to be medicines. A new threat to the industry is looming in the form of a proposed change to UK legislation which would make the MCA the sole arbiter over whether a product is classified a medicine, bypassing the courts.
You may also be interested in...
Aetion is also working with the US Food and Drug Administration and a number of biopharma companies on projects involving use of real-world evidence.
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.